Despite major advances in immunosuppressive regimens, which have greatly improved heart-transplant outcomes, drugs are still being developed and tested. In this review, data for the various available drugs and combined regimens are discussed, as well as those for novel drugs, in terms of efficacy and safety and cardiac allograft vasculopathy.
- Jon A Kobashigawa
- Jignesh K Patel
